Is the type of chronic pulmonary infection a determinant of lung function outcomes in adult patients with cystic fibrosis?

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 77, Issue 3-4, 2012, Pages 122-128

  Lopes, A J ^a   Mafort, T T ^b   De Sa Ferreira A ^c   Santos De Castro, M C ^b   De Cassia Firmida M ^b   De Andrade Marques, E ^b  

^a University of the State of Rio de Janeiro and Rehabilitation Science Graduate Program   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Augusto Motta University   (Brazil)

Author keywords

Cystic fibrosis; Genetics; Microbiology; Respiratory function tests

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACTERIUM; CHRONIC DISEASE; CHRONIC LUNG DISEASE; CHRONIC PULMONARY INFECTION; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC ANALYSIS; GLUCOSE TOLERANCE TEST; HEPATOMEGALY; HUMAN; ISOLATION AND PURIFICATION; LUNG; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MORTALITY; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA INFECTION; DISEASE ASSOCIATION; FORCED VITAL CAPACITY; HOMOZYGOSITY; LUNG INSUFFICIENCY; PANCREAS INSUFFICIENCY; PSEUDOMONAS AERUGINOSA; YOUNG ADULT;

ADULT; BACTERIA; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; ISOLATION AND PURIFICATION; LUNG; MALE; MICROBIOLOGY; PHYSIOPATHOLOGY; RESPIRATORY TRACT INFECTIONS;

EID: 84877285881     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Navarro J, Rainisio M, Harms HK, et al. Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. Eur Respir J 2001; 18: 298-305.
2. Simmonds NJ. Cystic fibrosis in the 21st century. Respir Med 2010; 24: 85-96.
3. Hodson ME, Simmonds NJ, Warwick WJ, et al. An international/multicentre report on patients with cystic fibrosis (CF) over the age of 40 years. J Cyst Fibros 2008; 7: 537-542.
4. Heijerman H, Westerman E, Conway S, et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus. J Cyst Fibros 2009; 8: 295-315.
5. Miller MB, Gilligan PH. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis J Clin Microbiol 2003; 41: 4009-4015.
6. Burkett A, Vandemheen KL, Giesbrecht-Lewis T, et al. Persistency of Pseudomonas aeruginosa in sputum cultures and clinical outcomes in adult patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2011; doi: 10.1007/s10096-011-1483-1488.
7. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
8. McPhail GL, Acton JD, Fenchel MC, et al. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic Pseudomonas aeruginosa infections, and dornase alfa use. J Pediatr 2008; 153: 752-757.
9. Konstan MW, Schluchter MD, Xue W, et al. Clinical use of ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 1084-1089.
10. Vrankrijker AMM, Wolfs TFW, van der Ent CK. Challenging and emerging pathogens in cystic fibrosis. Paediatr Respir Rev 2010; 11: 246-254.
11. Whiteford ML, Wilkinson JD, McColl JH, et al. Outcome of Burkholderia (Pseudomonas) cepacia colonization in children with cystic fibrosis following a hospital outbreak. Thorax 1995; 50: 1194-1198.
12. Liou TG, Adler FR, FitzSimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153: 345-352.
13. O'Connor GT, Quinton HB, Kahn R, et al. Case-mix adjustment for evaluation of mortality in cystic fibrosis. Pediatr Pulmonol 2002; 33: 483-491.
14. Johansen HK, Nir M, Hoiby N, et al. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet 1991; 337: 631-634.
15. Borgo G, Gasparini P, Bonizzato A, et al. Cystic fibrosis: the delta F508 mutation does not lead to an exceptionally severe phenotype. A cohort study. Eur J Pediatr 1993; 152: 1006-1011.
16. Farrel PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Consensus Report. J Pediatr 2008; 153: S4-S14.
17. Frederiksen B, Koch C, Høiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients. Pediatr Pulmonol 1999; 28: 159-166.
18. Borowitz D, Stevens C, Brettman LR, Campion M, Wilschanski M, Thompson H. Litrotamase long-term safety and support of nutritional status in pancreatic-insufficient cystic fibrosis. J Pediatr Gastroenterol Nutr 2012; 54: 248-257.
19. Hillman M, Eriksson L, Mared L, Helgesson K, Landin-Olsson M. Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus. J Cyst Fibros 2012; 11: 144-149.
20. Karlas T, Neuschulz M, Oltmanns A, et al. Non-invasive evaluation of cystic fibrosis related liver disease in adults with ARFI, transient elastography and different fibrosis scores. PLoS One 2012; 7: e42139.
21. Miller MR, Hankinson J, Brusasco V. ATS/ERS Task Force. Standardization of spirometry. Eur Respir J 2005; 26: 319-338.
22. Pereira CAC, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol 2007; 33: 397-406.
23. Sanders DB, Bittner RCL, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010; 182: 637-632.
24. Cunha Jr LG, Assis MC, Machado GB, et al. Potential mechanisms underlying the acute lung dysfunction and bacterial extrapulmonary dissemination during Burkholderia cenocepacia respiratory infection. Respir Res 2010; 11: doi: 10.1186/1465-9921-11-4.
25. Ren CL, Rosenfeld M, Mayer OH. Analysis of the associations between lung function and clinical features in preschool children with cystic fibrosis. Pediatr Pulmonol 2012; 47: 574-81.
26. Peterson-Carmichael SL, Harris WT, Goel R, et al. Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis. Pediatr Pulmonol 2009; 44: 503-511.
27. Moreau-Marquis S, Bomberger JM, Anderson GG, et al. The ?F508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 2008; 295: L25-L37.
28. Courtney JM, Bradley J, Mccaughan J, et al. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007; 42: 525-532.
29. Zar H, Saimann L, Quittell L, et al. Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 1995; 126:230-233.
30. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function iin cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA). Thorax 2002; 57: 596-601.
31. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992; 32: 1187-1191.
32. Saiman L. Microbiology of early CF lung disease. Paediatr Respir Rev 2004; 5 (Suppl A): S367-S369.
33. Salunkhe P, Smart CH, Morgan JA, et al. A cystic fibrosis epidemic strain of Pseudomonas aeruginosa displays enhanced virulence and antimicrobial resistance. J Bacteriol 2005; 187: 4908-4920.
34. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997; 131: 809-814.
35. Schaedel C, de Monestrol I, Hjelte L, et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 2002; 33: 483-491.
36. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc 2008; 108: 832-839.
37. Konstan MW, Butler SM, Wohl MEB, et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003; 142: 624-630.
38. Hart N, Tounian P, Clément A, et al. Nutritional status is an important predictor of diaphragm strength in young patients with cystic fibrosis. Am J Clin Nutr 2004; 80: 1201-1206.
39. Rochat T, Slosman D, Pichard C, Belli D. Body composition analysis by dual-energy X-ray absorptiometry in adults with cystic fibrosis. Chest 1994; 106: 800-805.
40. King S, Wilson J, Kotsimbos T, Bailey M, Nyulasi I. Body composition assessment in adults with cystic fibrosis: comparison of dual-energy X-ray absorptiometry with skinfolds and bioelectrical impedance analysis. Nutrition 2005; 21: 1087-1094.